Catalent (NYSE:CTLT) Stock Rating Reaffirmed by Robert W. Baird

Catalent (NYSE:CTLT)‘s stock had its “neutral” rating reiterated by analysts at Robert W. Baird in a note issued to investors on Tuesday, Benzinga reports. They presently have a $63.50 target price on the stock. Robert W. Baird’s target price indicates a potential upside of 6.31% from the company’s previous close.

A number of other analysts have also recently commented on the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. Barclays increased their target price on Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. StockNews.com began coverage on Catalent in a report on Wednesday, September 18th. They set a “sell” rating for the company. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $59.83.

Catalent Price Performance

CTLT opened at $59.73 on Tuesday. The company has a current ratio of 2.52, a quick ratio of 1.77 and a debt-to-equity ratio of 1.35. The company has a market cap of $10.81 billion, a price-to-earnings ratio of -9.79, a price-to-earnings-growth ratio of 1.88 and a beta of 1.15. The stock has a fifty day simple moving average of $59.52 and a two-hundred day simple moving average of $57.24. Catalent has a 12-month low of $31.80 and a 12-month high of $61.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The company had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.23 billion. Research analysts predict that Catalent will post 1.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Matti Masanovich sold 2,993 shares of the firm’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the transaction, the chief financial officer now directly owns 33,871 shares in the company, valued at approximately $1,921,840.54. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,409 shares of company stock worth $782,923. 0.31% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Catalent

A number of large investors have recently made changes to their positions in the company. Lindbrook Capital LLC boosted its stake in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after acquiring an additional 208 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalent during the second quarter valued at about $42,000. Mather Group LLC. purchased a new stake in Catalent in the first quarter worth about $52,000. Longfellow Investment Management Co. LLC raised its stake in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.